Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 98.63% is in line with its 5-year average of 99.54%, near the high end of its 5-year range (86.68%–100.00%).
0.88% below its 12-month average of 99.51%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
98.63%
GROSS MARGIN AVG TTM
99.51%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
99.54%
GROSS MARGIN AVG 10Y
100.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.88%
CURRENT VS 3Y AVG
-1.37%
CURRENT VS 5Y AVG
-0.91%
CURRENT VS 10Y AVG
-1.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
37.56%
median of 671 covered companies
CURRENT VS SECTOR MEDIAN
+162.59%
vs the sector median at left
CytomX Therapeutics, Inc.
Market Cap
$568.81M
Gross Margin
98.63%
TTM Avg
99.51%
3Y Avg
100.00%
5Y Avg
99.54%
Market Cap
$574.60M
Gross Margin
67.04%
TTM Avg
65.22%
3Y Avg
62.15%
5Y Avg
65.14%
Market Cap
$561.45M
Gross Margin
73.28%
TTM Avg
79.19%
3Y Avg
65.08%
5Y Avg
51.90%
Market Cap
$556.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$583.78M
Gross Margin
73.65%
TTM Avg
72.81%
3Y Avg
73.64%
5Y Avg
74.48%
Market Cap
$551.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$591.58M
Gross Margin
35.58%
TTM Avg
39.19%
3Y Avg
43.45%
5Y Avg
55.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $568.81M | 98.63% | 99.51% | 100.00% | 99.54% |
| CorMedix Inc. (CRMD)vs › | $566.03M | 82.78% | 90.56% | 68.85% | 51.96% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.60M | 67.04% | 65.22% | 62.15% | 65.14% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $561.45M | 73.28% | 79.19% | 65.08% | 51.90% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $556.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.78M | 73.65% | 72.81% | 73.64% | 74.48% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $551.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fulgent Genetics, Inc. (FLGT)vs › | $591.58M | 35.58% | 39.19% | 43.45% | 55.13% |
| Immix Biopharma, Inc. (IMMX)vs › | $540.21M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
98.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 97.55% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 94.60% |
| 2023-06-30 | 93.80% |
| 2023-03-31 | 93.63% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 86.68% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 92.48% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 100.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 100.00% |
| 2014-12-31 | 100.00% |
| 2014-09-30 | 100.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
